MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Associations between Exercise Classes and Self-Reported Exercise by People with Parkinson’s Disease at Parkinson’s Foundation Centers of Excellence

    E. Nettnin, S. Burrows, D. Simon, S. Wu, G. Miao, M. Rafferty (Chicago, USA)

    Objective: We sought to examine the relationship between the characteristics of Parkinson’s Foundation Center of Excellence (COE)-based and community-based exercise classes and the self-reported hours…
  • MDS Virtual Congress 2021

    Effect of simultaneous mGlu2 positive allosteric modulation and orthosteric stimulation combined with 5-HT2A antagonism on psychosis-like behaviours, dyskinesia and parkinsonism in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To assess the effects of concurrent metabotropic glutamate type 2 (mGlu2) positive allosteric modulation and orthosteric stimulation combined with serotonin type 2A (5-HT2A) antagonism.…
  • MDS Virtual Congress 2021

    Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.

    S. Oda, Y. Saitoh, J. Takei, S. Watanabe, Y. Mukai, Y. Takahashi (Kodaira, Japan)

    Objective: To evaluate whether Helicobactor pylori (H.pylori) infection affects the pharmacokinetics of L-DOPA in patients with Parkinson’s disease (PD). Background: H. pylori infects gastric mucosa…
  • MDS Virtual Congress 2021

    Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease

    W. Oertel, R. Pahwa, R. Hauser, M. Sale, G. Went (Marburg, Germany)

    Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…
  • MDS Virtual Congress 2021

    A French national multicentric prospective study of the 1-year impact of STN-DBS on speech in Parkinson’s disease: profile of progression and prognostic factors.

    T. Ollivier, S. Pinto, R. Viard, G. Kuchcinski, G. Touzet, L. Defebvre, D. Devos, C. Moreau (Lille, France)

    Objective: 1) To describe the evolution of speech in a large cohort of patients before and 1 year after STN-DBS. 2) To search for preoperative…
  • MDS Virtual Congress 2021

    Long-term real-world effectiveness of carbidopa/levodopa enteral suspension after 36 months of treatment initiation: Final results from PROviDE study

    R. Pahwa, S. Isaacson, R. Dorsey, D. Cella, B. Bluett, S. Thakkar, P. Kandukuri, N. Gupta, Y. Jalundhwala, Y. Bao, I. Pan, O. Ladhani, J. Aldred (Kansas City, USA)

    Objective: To examine the real-world long-term effectiveness of carbidopa/levodopa enteral suspension (CLES) on off time and other patient reported outcomes (PROs) among advanced Parkinson’s disease…
  • MDS Virtual Congress 2021

    Levodopa/carbidopa intestinal gel (LCIG) reduces fluctuations and shortens time to on without troublesome dyskinesia in advanced Parkinson’s Disease: Post-hoc analyses of 54-week LCIG-monotherapy trial

    R. Pahwa, J. Aldred, A. Merola, N. Gupta, E. Terasawa, V. Garcia-Horton, P. Kandukuri, Y. Jalundhwala, Y. Bao, O. Ladhani, S. Isaacson (Kansas City, USA)

    Objective: To assess the long-term effectiveness of LCIG monotherapy on reducing daily health-state fluctuations and time to on without troublesome dyskinesia (ONwoTD) after waking Background:…
  • MDS Virtual Congress 2021

    STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION

    G. Palermo, S. Giannoni, M. Giuntini, E. Belli, D. Frosini, G. Siciliano, R. Ceravolo (Pisa, Italy)

    Objective: To evaluate whether long-term statin use may affect motor progression in a large cohort of de novo patients with Parkinson's Disease. Background: Statins are…
  • MDS Virtual Congress 2021

    Community-Based Multidisciplinary Program for People with Parkinson Disease: A 2-year comparison

    S. Parveen, T. Passmore, B. Brickell, S. Jackson (Stillwater, USA)

    Objective: The current study reports outcomes from a 2 year-long community-based multidisciplinary program for individuals with Parkinson disease (PD) and their families based in Oklahoma…
  • MDS Virtual Congress 2021

    Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study

    N. Pavese, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Newcastle Upon Tyne, United Kingdom)

    Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of safinamide…
  • « Previous Page
  • 1
  • …
  • 952
  • 953
  • 954
  • 955
  • 956
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley